跳至主要内容
临床试验/TCTR20160122002
TCTR20160122002尚未招募未知

A randomized controlled trial of a regular diet as the first meal compared with traditional feeding in patients undergoing cesarean section

amphun Hospital0 个研究点目标入组 438 人开始时间: 2016年1月22日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
438

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
0 N/A (No limit) 至 0 N/A (No limit)(—)
性别
Female

入选标准

  • Pregnant women who were scheduled to undergo
  • section for various indications were enrolled in the
  • study after informed consent might have been

排除标准

  • The exclusion criteria included women with
  • severe uncontrolled medical conditions, e.g. diabetes mellitus, severe
  • pre-eclampsia/eclampsia where patient needed intensive
  • care in labour and post-partum, previous
  • bowel injury and previous surgery that involved
  • extensive lysis of adhesions of bowel.

研究者

发起方
amphun Hospital

相似试验

进行中(未招募)
1 期
An Efficacy and Safety Study of Alirocumab in Children and Adolescents with Heterozygous Familial HypercholesterolemiaHypercholesterolaemiaMedDRA version: 20.0Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disorders
EUCTR2017-001903-60-DKSanofi-aventis recherche & développement500
进行中(未招募)
1 期
An Efficacy and Safety Study of Alirocumab in Children and Adolescents with Heterozygous Familial HypercholesterolemiaHypercholesterolaemiaMedDRA version: 20.0Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disorders
EUCTR2017-001903-60-HUSanofi-aventis recherche & développement500
进行中(未招募)
1 期
Study to Evaluate the Safety and Efficacy of Crinecerfont in Pediatric Patients With Classic Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia (CAH)MedDRA version: 20.0Level: LLTClassification code 10010323Term: Congenital adrenal hyperplasiaSystem Organ Class: 100000004850
EUCTR2020-004381-19-ESeurocrine Biosciences, Inc.81
进行中(未招募)
1 期
This is a Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response to Biologic and/or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs)Moderate to Severe Rheumatoid ArthritisMedDRA version: 23.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
EUCTR2020-005303-39-GRAbbVie Deutschland GmbH & Co. KG425
进行中(未招募)
不适用
A study to evaluate the effect and safety of a 4 week treatment plan of Alirocumab in patients with high cholesterolPrimary HypercholesterolemiaMedDRA version: 16.1Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861
EUCTR2013-002343-29-SKRegeneron Pharmaceuticals, Inc.803